JP2017528487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528487A5 JP2017528487A5 JP2017515059A JP2017515059A JP2017528487A5 JP 2017528487 A5 JP2017528487 A5 JP 2017528487A5 JP 2017515059 A JP2017515059 A JP 2017515059A JP 2017515059 A JP2017515059 A JP 2017515059A JP 2017528487 A5 JP2017528487 A5 JP 2017528487A5
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- methyl
- amino
- chloro
- dihydroquinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 52
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical class 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- -1 each C 1 -C 6 alkyl Chemical group 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 229910052805 deuterium Inorganic materials 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- DKGZUENOTCHHGB-UHFFFAOYSA-N 5-[(6-chloro-2-oxo-1H-quinolin-3-yl)methylamino]-6-oxo-1H-pyridine-3-carboxylic acid Chemical compound C1=CC2=C(C=C1Cl)C=C(C(=O)N2)CNC3=CC(=CNC3=O)C(=O)O DKGZUENOTCHHGB-UHFFFAOYSA-N 0.000 claims description 2
- HPOPOVVUDKGCAN-LBPRGKRZSA-N CC(C)OC1=CC2=C(C=C1Cl)C=C([C@H](C)NC1=CC=C(C#N)N(C)C1=O)C(=O)N2 Chemical compound CC(C)OC1=CC2=C(C=C1Cl)C=C([C@H](C)NC1=CC=C(C#N)N(C)C1=O)C(=O)N2 HPOPOVVUDKGCAN-LBPRGKRZSA-N 0.000 claims description 2
- VIKJAIUMEYADPO-UHFFFAOYSA-N CC(NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(OCC1CC(F)(F)C1)C(Cl)=C2 Chemical compound CC(NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(OCC1CC(F)(F)C1)C(Cl)=C2 VIKJAIUMEYADPO-UHFFFAOYSA-N 0.000 claims description 2
- PDMDNRKCRBOWOM-UHFFFAOYSA-N CN1C(=O)C(NCC2=CC3=C(NC2=O)C=CC(Cl)=C3)=CC=C1C#N Chemical compound CN1C(=O)C(NCC2=CC3=C(NC2=O)C=CC(Cl)=C3)=CC=C1C#N PDMDNRKCRBOWOM-UHFFFAOYSA-N 0.000 claims description 2
- SWRGOIPVPPLYDR-UHFFFAOYSA-N CN1C=CC=C(NCC2=CC3=C(NC2=O)C=C(OCC2=NC=CC=C2)C(Cl)=C3)C1=O Chemical compound CN1C=CC=C(NCC2=CC3=C(NC2=O)C=C(OCC2=NC=CC=C2)C(Cl)=C3)C1=O SWRGOIPVPPLYDR-UHFFFAOYSA-N 0.000 claims description 2
- NSSCFMGYDFCYNL-UHFFFAOYSA-N COC1=CC2=C(C=C1Cl)C=C(C(C)NC1=CC=C(C#N)N(C)C1=O)C(=O)N2 Chemical compound COC1=CC2=C(C=C1Cl)C=C(C(C)NC1=CC=C(C#N)N(C)C1=O)C(=O)N2 NSSCFMGYDFCYNL-UHFFFAOYSA-N 0.000 claims description 2
- NSSCFMGYDFCYNL-SNVBAGLBSA-N COC1=CC2=C(C=C1Cl)C=C([C@@H](C)NC1=CC=C(C#N)N(C)C1=O)C(=O)N2 Chemical compound COC1=CC2=C(C=C1Cl)C=C([C@@H](C)NC1=CC=C(C#N)N(C)C1=O)C(=O)N2 NSSCFMGYDFCYNL-SNVBAGLBSA-N 0.000 claims description 2
- TZKQLILAWIHUMT-SECBINFHSA-N C[C@@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(F)C(Cl)=C2 Chemical compound C[C@@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(F)C(Cl)=C2 TZKQLILAWIHUMT-SECBINFHSA-N 0.000 claims description 2
- PJBUFTGEHWYEER-CQSZACIVSA-N C[C@@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(OCC1=NC=CC=C1)C(Cl)=C2 Chemical compound C[C@@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(OCC1=NC=CC=C1)C(Cl)=C2 PJBUFTGEHWYEER-CQSZACIVSA-N 0.000 claims description 2
- ZPOAXBRGKZGJGA-VIFPVBQESA-N C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C(F)=CC(Cl)=C2 Chemical compound C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C(F)=CC(Cl)=C2 ZPOAXBRGKZGJGA-VIFPVBQESA-N 0.000 claims description 2
- BWHIFDUXXABGMM-NSHDSACASA-N C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(C(Cl)=C2)C(C)(C)O Chemical compound C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(C(Cl)=C2)C(C)(C)O BWHIFDUXXABGMM-NSHDSACASA-N 0.000 claims description 2
- TZKQLILAWIHUMT-VIFPVBQESA-N C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(F)C(Cl)=C2 Chemical compound C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(F)C(Cl)=C2 TZKQLILAWIHUMT-VIFPVBQESA-N 0.000 claims description 2
- CYFQOPAAZZVBQG-NSHDSACASA-N C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(N1CC(F)(F)C1)C(Cl)=C2 Chemical compound C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(N1CC(F)(F)C1)C(Cl)=C2 CYFQOPAAZZVBQG-NSHDSACASA-N 0.000 claims description 2
- PJBUFTGEHWYEER-AWEZNQCLSA-N C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(OCC1=NC=CC=C1)C(Cl)=C2 Chemical compound C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(OCC1=NC=CC=C1)C(Cl)=C2 PJBUFTGEHWYEER-AWEZNQCLSA-N 0.000 claims description 2
- MWYSDNPPAIJPJV-LBPRGKRZSA-N C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(OCC1CC1)C(Cl)=C2 Chemical compound C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=C(OCC1CC1)C(Cl)=C2 MWYSDNPPAIJPJV-LBPRGKRZSA-N 0.000 claims description 2
- SEEDZPLNIRDCAL-JTQLQIEISA-N C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)N=C(C1CC1)C(Cl)=C2 Chemical compound C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)N=C(C1CC1)C(Cl)=C2 SEEDZPLNIRDCAL-JTQLQIEISA-N 0.000 claims description 2
- CYAKHPACTXYEPK-NSHDSACASA-N C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)N=C(N1CCC1)C(Cl)=C2 Chemical compound C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)N=C(N1CCC1)C(Cl)=C2 CYAKHPACTXYEPK-NSHDSACASA-N 0.000 claims description 2
- ARMGVRSPXQMERQ-VIFPVBQESA-N C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)N=CC(Cl)=C2 Chemical compound C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)N=CC(Cl)=C2 ARMGVRSPXQMERQ-VIFPVBQESA-N 0.000 claims description 2
- JEDNKDBKPFUMBB-VIFPVBQESA-N C[C@H](NC1=CC=C(C#N)N(C1=O)C(F)(F)F)C1=CC2=C(NC1=O)C=CC(Cl)=C2 Chemical compound C[C@H](NC1=CC=C(C#N)N(C1=O)C(F)(F)F)C1=CC2=C(NC1=O)C=CC(Cl)=C2 JEDNKDBKPFUMBB-VIFPVBQESA-N 0.000 claims description 2
- LVEMRGVOUYXDFD-VIFPVBQESA-N C[C@H](NC1=CC=C(N(C)C1=O)C(N)=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2 Chemical compound C[C@H](NC1=CC=C(N(C)C1=O)C(N)=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2 LVEMRGVOUYXDFD-VIFPVBQESA-N 0.000 claims description 2
- GSMIYCKMLOSJBR-JTQLQIEISA-N C[C@H](NC1=CC=C(N2C=NN=N2)N(C)C1=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2 Chemical compound C[C@H](NC1=CC=C(N2C=NN=N2)N(C)C1=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2 GSMIYCKMLOSJBR-JTQLQIEISA-N 0.000 claims description 2
- UXVGPOVENBADCI-VIFPVBQESA-N C[C@H](NC1=CC=C(NC1=O)C#N)C1=CC2=C(NC1=O)C=CC(Cl)=C2 Chemical compound C[C@H](NC1=CC=C(NC1=O)C#N)C1=CC2=C(NC1=O)C=CC(Cl)=C2 UXVGPOVENBADCI-VIFPVBQESA-N 0.000 claims description 2
- UHPKLGPKLHHNCW-VIFPVBQESA-N C[C@H](NC1=NC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2 Chemical compound C[C@H](NC1=NC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2 UHPKLGPKLHHNCW-VIFPVBQESA-N 0.000 claims description 2
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims description 2
- MMEAODLKSRHAIR-UHFFFAOYSA-N ClC1=CC2=C(NC(=O)C(CNC3=CC=C(Br)NC3=O)=C2)C=C1 Chemical compound ClC1=CC2=C(NC(=O)C(CNC3=CC=C(Br)NC3=O)=C2)C=C1 MMEAODLKSRHAIR-UHFFFAOYSA-N 0.000 claims description 2
- BJRNSMBACDBVMT-UHFFFAOYSA-N ClC1=CC2=C(NC(=O)C(CNC3=CC=C(NC3=O)C#N)=C2)C=C1 Chemical compound ClC1=CC2=C(NC(=O)C(CNC3=CC=C(NC3=O)C#N)=C2)C=C1 BJRNSMBACDBVMT-UHFFFAOYSA-N 0.000 claims description 2
- SLCDOTDJNCIYCJ-SECBINFHSA-N ClC1=CC=C2NC(C(=NC2=C1)[C@@H](C)NC1=CC=C(N(C1=O)C)C#N)=O Chemical compound ClC1=CC=C2NC(C(=NC2=C1)[C@@H](C)NC1=CC=C(N(C1=O)C)C#N)=O SLCDOTDJNCIYCJ-SECBINFHSA-N 0.000 claims description 2
- GAGJFBRIVDHXBX-UHFFFAOYSA-N ClC=1C=C2C=C(C(NC2=CC=1)=O)CNC=1C(N(C(=CC=1)C(F)(F)F)C)=O Chemical compound ClC=1C=C2C=C(C(NC2=CC=1)=O)CNC=1C(N(C(=CC=1)C(F)(F)F)C)=O GAGJFBRIVDHXBX-UHFFFAOYSA-N 0.000 claims description 2
- HONGYFQTPGJGNF-UHFFFAOYSA-N ClC=1C=C2C=C(C(NC2=CC=1)=O)CNC=1C(N(C(=CC=1)C)C)=O Chemical compound ClC=1C=C2C=C(C(NC2=CC=1)=O)CNC=1C(N(C(=CC=1)C)C)=O HONGYFQTPGJGNF-UHFFFAOYSA-N 0.000 claims description 2
- LEVPMQPHTKJABL-UHFFFAOYSA-N ClC=1C=C2C=C(C(NC2=CC=1)=O)CNC=1C(N(C=CC=1)C)=O Chemical compound ClC=1C=C2C=C(C(NC2=CC=1)=O)CNC=1C(N(C=CC=1)C)=O LEVPMQPHTKJABL-UHFFFAOYSA-N 0.000 claims description 2
- DHDHUTUALAFFMG-UHFFFAOYSA-N ClC=1C=C2C=C(C(NC2=CC=1)=O)CNC=1C(N(C=CC=1)C1CC1)=O Chemical compound ClC=1C=C2C=C(C(NC2=CC=1)=O)CNC=1C(N(C=CC=1)C1CC1)=O DHDHUTUALAFFMG-UHFFFAOYSA-N 0.000 claims description 2
- GWBZTYSDSZBEJE-UHFFFAOYSA-N ClC=1C=C2C=C(C(NC2=CC=1)=O)CNC=1C(N(C=CC=1)CC)=O Chemical compound ClC=1C=C2C=C(C(NC2=CC=1)=O)CNC=1C(N(C=CC=1)CC)=O GWBZTYSDSZBEJE-UHFFFAOYSA-N 0.000 claims description 2
- AMGSLPSFZAJSOA-UHFFFAOYSA-N ClC=1C=C2C=C(C(NC2=CC=1)=O)CNC=1C(NC(=CC=1)C(F)(F)F)=O Chemical compound ClC=1C=C2C=C(C(NC2=CC=1)=O)CNC=1C(NC(=CC=1)C(F)(F)F)=O AMGSLPSFZAJSOA-UHFFFAOYSA-N 0.000 claims description 2
- NEQYWYXGTJDAKR-SNVBAGLBSA-N ClC=1C=C2C=C(C(NC2=CC=1)=O)[C@@H](C)NC1=CC=C(N(C1=O)C)C#N Chemical compound ClC=1C=C2C=C(C(NC2=CC=1)=O)[C@@H](C)NC1=CC=C(N(C1=O)C)C#N NEQYWYXGTJDAKR-SNVBAGLBSA-N 0.000 claims description 2
- TZKQLILAWIHUMT-UHFFFAOYSA-N ClC=1C=C2C=C(C(NC2=CC=1F)=O)C(C)NC1=CC=C(N(C1=O)C)C#N Chemical compound ClC=1C=C2C=C(C(NC2=CC=1F)=O)C(C)NC1=CC=C(N(C1=O)C)C#N TZKQLILAWIHUMT-UHFFFAOYSA-N 0.000 claims description 2
- GMHCMYUQVXEYLF-LBPRGKRZSA-N ClC=1C=C2C=C(C(NC2=CC=1NCC(C)(C)O)=O)[C@H](C)NC1=CC=C(N(C1=O)C)C#N Chemical compound ClC=1C=C2C=C(C(NC2=CC=1NCC(C)(C)O)=O)[C@H](C)NC1=CC=C(N(C1=O)C)C#N GMHCMYUQVXEYLF-LBPRGKRZSA-N 0.000 claims description 2
- DAJPKGHXCGODGX-UHFFFAOYSA-N ClC=1C=C2C=C(C(NC2=CC=1OC)=O)CNC=1C(N(C=CC=1)C)=O Chemical compound ClC=1C=C2C=C(C(NC2=CC=1OC)=O)CNC=1C(N(C=CC=1)C)=O DAJPKGHXCGODGX-UHFFFAOYSA-N 0.000 claims description 2
- NSSCFMGYDFCYNL-JTQLQIEISA-N ClC=1C=C2C=C(C(NC2=CC=1OC)=O)[C@H](C)NC1=CC=C(N(C1=O)C)C#N Chemical compound ClC=1C=C2C=C(C(NC2=CC=1OC)=O)[C@H](C)NC1=CC=C(N(C1=O)C)C#N NSSCFMGYDFCYNL-JTQLQIEISA-N 0.000 claims description 2
- PJBUFTGEHWYEER-UHFFFAOYSA-N ClC=1C=C2C=C(C(NC2=CC=1OCC1=NC=CC=C1)=O)C(C)NC1=CC=C(N(C1=O)C)C#N Chemical compound ClC=1C=C2C=C(C(NC2=CC=1OCC1=NC=CC=C1)=O)C(C)NC1=CC=C(N(C1=O)C)C#N PJBUFTGEHWYEER-UHFFFAOYSA-N 0.000 claims description 2
- UFQKUWOMVVXDCG-VIFPVBQESA-N ClC=1C=C2C=C(C(NC2=NC=1C)=O)[C@H](C)NC1=CC=C(N(C1=O)C)C#N Chemical compound ClC=1C=C2C=C(C(NC2=NC=1C)=O)[C@H](C)NC1=CC=C(N(C1=O)C)C#N UFQKUWOMVVXDCG-VIFPVBQESA-N 0.000 claims description 2
- JOSPMXZAMORKSR-LBPRGKRZSA-N N1(CCC1)C1=C(C=C2C=C(C(NC2=C1)=O)[C@H](C)NC1=CC=C(N(C1=O)C)C#N)Cl Chemical compound N1(CCC1)C1=C(C=C2C=C(C(NC2=C1)=O)[C@H](C)NC1=CC=C(N(C1=O)C)C#N)Cl JOSPMXZAMORKSR-LBPRGKRZSA-N 0.000 claims description 2
- 101710134866 Quinone reductase Proteins 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 claims description 2
- NEQYWYXGTJDAKR-JTQLQIEISA-N olutasidenib Chemical compound C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2 NEQYWYXGTJDAKR-JTQLQIEISA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 4
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- SLCDOTDJNCIYCJ-VIFPVBQESA-N C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=NC2=CC(Cl)=CC=C2NC1=O Chemical compound C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=NC2=CC(Cl)=CC=C2NC1=O SLCDOTDJNCIYCJ-VIFPVBQESA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053006P | 2014-09-19 | 2014-09-19 | |
| US62/053,006 | 2014-09-19 | ||
| US201562128089P | 2015-03-04 | 2015-03-04 | |
| US62/128,089 | 2015-03-04 | ||
| US201562150812P | 2015-04-21 | 2015-04-21 | |
| US62/150,812 | 2015-04-21 | ||
| PCT/US2015/051055 WO2016044789A1 (en) | 2014-09-19 | 2015-09-18 | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017528487A JP2017528487A (ja) | 2017-09-28 |
| JP2017528487A5 true JP2017528487A5 (enExample) | 2019-10-10 |
| JP6648115B2 JP6648115B2 (ja) | 2020-02-14 |
Family
ID=54291606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515059A Active JP6648115B2 (ja) | 2014-09-19 | 2015-09-18 | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体 |
Country Status (37)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6067226B2 (ja) | 2009-03-13 | 2017-01-25 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞増殖関連疾患のための方法および組成物 |
| ES2594402T3 (es) * | 2009-10-21 | 2016-12-20 | Agios Pharmaceuticals, Inc. | Métodos y composiciones para trastornos relacionados con la proliferación celular |
| HRP20241145T1 (hr) | 2014-02-06 | 2024-11-22 | Nxera Pharma Uk Limited | Biciklički aza spojevi kao agonisti muskarinskih receptora |
| EP3194383B1 (en) | 2014-09-19 | 2019-11-06 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| AU2015316796A1 (en) | 2014-09-19 | 2017-03-30 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as Bub1 inhibitors |
| US10005734B2 (en) | 2014-09-19 | 2018-06-26 | Forma Therapeutics, Inc. | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| JP6751081B2 (ja) | 2014-09-19 | 2020-09-02 | フォーマ セラピューティクス，インコーポレイテッド | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体 |
| HUE062424T2 (hu) | 2014-09-19 | 2023-11-28 | Forma Therapeutics Inc | Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok |
| EP3237385B1 (en) * | 2014-12-22 | 2021-11-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Mutant idh1 inhibitors useful for treating cancer |
| WO2016171756A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| US10294206B2 (en) | 2015-04-21 | 2019-05-21 | Forma Tm2, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| EP3619196B1 (de) | 2017-05-04 | 2022-03-30 | Bayer CropScience Aktiengesellschaft | 2-{[2-(phenyloxymethyl)pyridin-5-yl]oxy}-ethanamin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel z.b. für den pflanzenschutz |
| SI3720442T1 (sl) | 2018-05-16 | 2023-06-30 | Forma Therapeutics, Inc. | Zaviranje mutantnega IDF-1 |
| WO2020232381A1 (en) | 2019-05-16 | 2020-11-19 | Forma Therapeutics, Inc. | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) |
| WO2019222553A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US11013733B2 (en) * | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11013734B2 (en) * | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US10532047B2 (en) | 2018-05-16 | 2020-01-14 | Forma Therapeutics, Inc. | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| TW202104207A (zh) * | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| US11566013B1 (en) * | 2019-11-20 | 2023-01-31 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1) |
| CN112321571B (zh) * | 2020-10-27 | 2022-06-03 | 浙江工业大学 | 2-呋喃-喹啉-4-甲酰胺类化合物及其应用 |
| CN112341389B (zh) * | 2020-10-27 | 2022-07-29 | 浙江工业大学 | 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用 |
| CN115850240B (zh) * | 2022-12-28 | 2023-09-19 | 北京康立生医药技术开发有限公司 | 一种治疗急性髓系白血病药物奥卢他西尼的合成方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99731A0 (en) | 1990-10-18 | 1992-08-18 | Merck & Co Inc | Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US20030105124A1 (en) | 2000-04-27 | 2003-06-05 | Susan Beth Sobolov-Jaynes | Substituted benzolactam compounds |
| WO2003106452A2 (en) | 2002-06-12 | 2003-12-24 | Millennium Pharmaceuticals, Inc. | Antagonists of melanin concentrating hormone receptor |
| JPWO2004043936A1 (ja) | 2002-11-14 | 2006-03-09 | 協和醗酵工業株式会社 | Ｐｌｋ阻害剤 |
| RU2284325C2 (ru) * | 2003-12-17 | 2006-09-27 | Общество С Ограниченной Ответственностью "Асинэкс Медхим" | Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе |
| JPWO2005095382A1 (ja) | 2004-03-30 | 2007-08-16 | 協和醗酵工業株式会社 | 抗腫瘍剤 |
| WO2006054912A1 (fr) | 2004-11-18 | 2006-05-26 | Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' | Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base |
| TW200803855A (en) | 2006-02-24 | 2008-01-16 | Kalypsys Inc | Quinolones useful as inducible nitric oxide synthase inhibitors |
| EP2044068A4 (en) * | 2006-07-17 | 2010-07-21 | Merck Sharp & Dohme | 1-HYDROXY Naphthyridine Compounds as Anti- HIV Drugs |
| JP2010043004A (ja) | 2006-12-06 | 2010-02-25 | Dainippon Sumitomo Pharma Co Ltd | 新規２環性複素環化合物 |
| WO2008131547A1 (en) | 2007-04-30 | 2008-11-06 | Prometic Biosciences Inc. | 'triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives' |
| WO2010144338A1 (en) | 2009-06-08 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
| JP5967827B2 (ja) * | 2009-12-09 | 2016-08-10 | アジオス ファーマシューティカルズ， インコーポレイテッド | Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物 |
| WO2012006104A2 (en) | 2010-06-28 | 2012-01-12 | Academia Sinica, Taiwan | Compounds and methods for treating tuberculosis infection |
| CN102558049B (zh) * | 2010-12-17 | 2015-02-04 | 中国科学院上海药物研究所 | 一类双香豆素类化合物及其制备方法和用途 |
| US20120184548A1 (en) | 2011-01-19 | 2012-07-19 | Romyr Dominique | Carboxylic acid aryl amides |
| US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN103814020B (zh) * | 2011-06-17 | 2017-07-14 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| JP6026544B2 (ja) | 2011-09-27 | 2016-11-16 | ノバルティス アーゲー | 変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類 |
| EP2793881B1 (en) | 2011-12-21 | 2018-10-31 | The Regents of the University of Colorado | Anti-cancer compounds targeting ral gtpase |
| CA2860623A1 (en) | 2012-01-06 | 2013-07-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| MX2015012822A (es) * | 2013-03-14 | 2016-05-31 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. |
| WO2015003146A1 (en) | 2013-07-03 | 2015-01-08 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| WO2015121210A1 (en) | 2014-02-11 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| US10005734B2 (en) | 2014-09-19 | 2018-06-26 | Forma Therapeutics, Inc. | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| JP6751081B2 (ja) | 2014-09-19 | 2020-09-02 | フォーマ セラピューティクス，インコーポレイテッド | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体 |
| EP3194383B1 (en) | 2014-09-19 | 2019-11-06 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| HUE062424T2 (hu) | 2014-09-19 | 2023-11-28 | Forma Therapeutics Inc | Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok |
| EP3237385B1 (en) | 2014-12-22 | 2021-11-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Mutant idh1 inhibitors useful for treating cancer |
| GB2533925A (en) | 2014-12-31 | 2016-07-13 | Univ Bath | Antimicrobial compounds, compositions and methods |
| WO2016171756A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| US10294206B2 (en) | 2015-04-21 | 2019-05-21 | Forma Tm2, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US10253041B2 (en) | 2015-07-27 | 2019-04-09 | Eli Lilly And Company | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors |
| EP3419593B1 (en) | 2016-02-26 | 2022-03-23 | Celgene Corporation | Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia |
| CN109311863B (zh) | 2016-06-06 | 2021-10-29 | 伊莱利利公司 | 突变型idh1抑制剂 |
| JP6987798B2 (ja) | 2016-06-22 | 2022-01-05 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 癌の治療に変異体ｉｄｈ１阻害剤として有用なチアゾール誘導体 |
| TN2019000158A1 (en) | 2016-12-16 | 2020-10-05 | Lilly Co Eli | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
-
2015
- 2015-09-18 HU HUE20157755A patent/HUE062424T2/hu unknown
- 2015-09-18 PT PT201577558T patent/PT3733662T/pt unknown
- 2015-09-18 MX MX2019013203A patent/MX385512B/es unknown
- 2015-09-18 MX MX2017003404A patent/MX2017003404A/es active IP Right Grant
- 2015-09-18 RS RS20200418A patent/RS60140B1/sr unknown
- 2015-09-18 IL IL292608A patent/IL292608B2/en unknown
- 2015-09-18 US US14/858,167 patent/US9834539B2/en active Active
- 2015-09-18 ES ES20157755T patent/ES2953347T3/es active Active
- 2015-09-18 SM SM20200212T patent/SMT202000212T1/it unknown
- 2015-09-18 KR KR1020177010585A patent/KR102209667B1/ko active Active
- 2015-09-18 RS RS20181586A patent/RS58184B1/sr unknown
- 2015-09-18 CN CN202311265288.0A patent/CN117695280A/zh active Pending
- 2015-09-18 EP EP23176702.1A patent/EP4257131A3/en active Pending
- 2015-09-18 LT LTEP18198969.0T patent/LT3447050T/lt unknown
- 2015-09-18 JP JP2017515059A patent/JP6648115B2/ja active Active
- 2015-09-18 ES ES18198969T patent/ES2790640T3/es active Active
- 2015-09-18 PL PL18198969T patent/PL3447050T3/pl unknown
- 2015-09-18 PT PT181989690T patent/PT3447050T/pt unknown
- 2015-09-18 ES ES15778433T patent/ES2704897T3/es active Active
- 2015-09-18 MA MA053352A patent/MA53352A/fr unknown
- 2015-09-18 PT PT15778433T patent/PT3194376T/pt unknown
- 2015-09-18 DK DK15778433.1T patent/DK3194376T3/en active
- 2015-09-18 MY MYPI2020001463A patent/MY197533A/en unknown
- 2015-09-18 CA CA2961817A patent/CA2961817C/en active Active
- 2015-09-18 ME MEP-2020-78A patent/ME03776B/me unknown
- 2015-09-18 PL PL15778433T patent/PL3194376T3/pl unknown
- 2015-09-18 NZ NZ73037315A patent/NZ730373A/en unknown
- 2015-09-18 MY MYPI2017700895A patent/MY176250A/en unknown
- 2015-09-18 CN CN201580050441.5A patent/CN107001328B/zh active Active
- 2015-09-18 SG SG11201702194SA patent/SG11201702194SA/en unknown
- 2015-09-18 PL PL20157755.8T patent/PL3733662T3/pl unknown
- 2015-09-18 FI FIEP20157755.8T patent/FI3733662T3/fi active
- 2015-09-18 WO PCT/US2015/051055 patent/WO2016044789A1/en not_active Ceased
- 2015-09-18 SM SM20190018T patent/SMT201900018T1/it unknown
- 2015-09-18 EP EP18198969.0A patent/EP3447050B1/en active Active
- 2015-09-18 CN CN202010391529.6A patent/CN111909130B/zh active Active
- 2015-09-18 HU HUE15778433A patent/HUE041460T2/hu unknown
- 2015-09-18 EP EP20157755.8A patent/EP3733662B1/en active Active
- 2015-09-18 EP EP15778433.1A patent/EP3194376B1/en active Active
- 2015-09-18 DK DK18198969.0T patent/DK3447050T3/da active
- 2015-09-18 EA EA201790657A patent/EA034336B1/ru unknown
- 2015-09-18 AU AU2015317329A patent/AU2015317329B2/en active Active
- 2015-09-18 SI SI201530537T patent/SI3194376T1/sl unknown
- 2015-09-18 PE PE2017000471A patent/PE20171056A1/es unknown
- 2015-09-18 BR BR112017005238-5A patent/BR112017005238B1/pt active IP Right Grant
- 2015-09-18 TW TW104131044A patent/TWI686390B/zh active
- 2015-09-18 LT LTEP15778433.1T patent/LT3194376T/lt unknown
- 2015-09-18 MA MA040481A patent/MA40481A/fr unknown
- 2015-09-18 PH PH1/2017/500517A patent/PH12017500517B1/en unknown
- 2015-09-18 SI SI201531117T patent/SI3447050T1/sl unknown
-
2017
- 2017-03-07 US US15/452,256 patent/US20170174658A1/en not_active Abandoned
- 2017-03-14 IL IL251163A patent/IL251163B/en active IP Right Grant
- 2017-03-17 CL CL2017000658A patent/CL2017000658A1/es unknown
- 2017-03-19 SA SA517381129A patent/SA517381129B1/ar unknown
- 2017-03-27 ZA ZA2017/02127A patent/ZA201702127B/en unknown
- 2017-04-03 CO CONC2017/0003241A patent/CO2017003241A2/es unknown
- 2017-04-13 EC ECIEPI201722933A patent/ECSP17022933A/es unknown
-
2018
- 2018-04-27 US US15/964,844 patent/US10414752B2/en active Active
-
2019
- 2019-01-21 CY CY20191100075T patent/CY1121149T1/el unknown
- 2019-03-01 US US16/290,240 patent/US10550098B2/en active Active
- 2019-04-17 ZA ZA2019/02446A patent/ZA201902446B/en unknown
- 2019-12-12 US US16/712,951 patent/US10889567B2/en active Active
- 2019-12-16 AU AU2019283765A patent/AU2019283765B2/en active Active
-
2020
- 2020-04-24 HR HRP20200666TT patent/HRP20200666T1/hr unknown
- 2020-05-04 CY CY20201100407T patent/CY1122865T1/el unknown
- 2020-11-23 US US17/101,018 patent/US11498913B2/en active Active
-
2021
- 2021-04-18 IL IL282363A patent/IL282363B/en unknown
- 2021-08-10 AU AU2021215141A patent/AU2021215141B2/en active Active
-
2022
- 2022-11-09 US US17/984,069 patent/US20230125739A1/en not_active Abandoned
-
2023
- 2023-04-14 ZA ZA2023/04409A patent/ZA202304409B/en unknown
- 2023-11-09 US US18/506,060 patent/US12275715B2/en active Active